During the past decade, Centre Hospitalier de La Cote Basque; Oncologie conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Centre Hospitalier de La Cote Basque; Oncologie" are "Breast Cancer" (1 trials), "Colorectal Cancer" (1 trials) and "Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer" (1 trials). Many other conditions were trialed in "Centre Hospitalier de La Cote Basque; Oncologie" in a lesser frequency.

Most popular intervention types in "Centre Hospitalier de La Cote Basque; Oncologie" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Giredestrant" (1 trials), "Giredestrant-matched Placebo" (1 trials), "LHRH Agonist" (1 trials), "Letrozole" (1 trials) and "Letrozole-matched Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centre Hospitalier de La Cote Basque; Oncologie" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Centre Hospitalier de La Cote Basque; Oncologie". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Centre Hospitalier de La Cote Basque; Oncologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centre Hospitalier de La Cote Basque; Oncologie, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".